Navigation Links
ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
Date:9/10/2007

ere observed in a single-arm trial with ERBITUX, delayed, accelerated (concomitant boost) fractionation radiation therapy, and cisplatin (100 mg/m2) conducted in patients with locally advanced squamous cell carcinoma of the head and neck. Two of 21 patients died, one as a result of pneumonia and one of an unknown cause. Four patients discontinued treatment due to adverse events. Two of these discontinuations were due to cardiac events (myocardial infarction in one patient and arrhythmia, diminished cardiac output, and hypotension in the other patient).

In women of childbearing potential, appropriate contraceptive measures must be used during treatment with ERBITUX and for 6 months following the last dose of ERBITUX. If ERBITUX is used during pregnancy or if patients become pregnant while receiving ERBITUX , patients should be apprised of the potential risk for loss of pregnancy or potential hazard to the fetus.

The incidence of hypomagnesemia (both overall and severe [NCI CTC Grades 3 & 4]) was increased in patients receiving ERBITUX alone or in combination with chemotherapy as compared to those receiving best supportive care or chemotherapy alone based on ongoing, controlled clinical trials in 244 patients. Approximately one-half of these patients receiving ERBITUX experienced hypomagnesemia and 10-15% experienced severe hypomagnesemia. Electrolyte repletion was necessary in some patients and in severe cases, intravenous replacement was required. Patients receiving ERBITUX therapy should be periodically monitored for hypomagnesemia, and accompanying hypocalcemia and hypokalemia during, and up to 8 weeks following the completion of, ERBITUX therapy.

The most serious adverse reactions associated with ERBITUX in combination with radiation therapy in 208 patients with head and neck cancer were infusion reaction (3%), cardiopulmonary arrest (2%), dermatologic toxicity (2.5%), mucositis (6%), radiation dermatitis (3%), confusion (2%), and diarrhea (2%).
'/>"/>

SOURCE ImClone Systems Incorporated; Bristol-Myers Squibb Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. ENDEAVOR IV Clinical Trial Meets Primary Endpoint
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
4. Neoprobe Phase 2 Lymphoseek Trial Meets Primary Endpoint
5. Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
6. SciClone and Sigma-Tau Report Thymalfasin Meets Primary Endpoint in Phase 2 Malignant Melanoma Trial
7. GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets Phase II Study Endpoints of Immunogenicity and Safety Compared to Licensed Vaccines
8. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
9. DX-88 for Hereditary Angioedema Meets Primary and Secondary Endpoints in Phase 3 Trial (EDEMA3)
10. Alexzas AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating Schizophrenic Patients With Acute Agitation
11. Replidyne Phase II Pediatric Trial Meets Primary Objective
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Ohio , Jan. 15, 2014  A novel wearable injector ... easy and painless for patients to self-inject prescription drugs in ... disorders, including cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to grow to $220B by 2018, according to analysts.   Many ...
(Date:1/14/2014)... AUSTIN, Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... report results for the fourth quarter of 2013 on Monday, ... scheduled for release after the close of trading. ... a conference call to discuss the operating highlights and financial ...
(Date:1/14/2014)... Calif. , Jan. 14, 2014 The Brandeis Medical Center, ... Angeles a premier and affordable laser tattoo removal experience ... Dr. Brandeis, focus is in providing high quality cosmetic services with ... patients. " Southern California has seen ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... 2011 Omeros Corporation (Nasdaq: OMER ) today ... Regents of the University of California to a new series ... advance in the control of surgical and traumatic bleeding. ... represents a potential life-saving treatment for patients. With the withdrawal ...
... 5, 2011 CutisPharma, Inc. announced the introduction ... Mary,s Mouthwash compounding kits. These products complete the ... line already includes FIRST® - Mouthwash BLM, and ... FIRST® - Duke,s Mouthwash are comparable to those ...
Cached Medicine Technology:Omeros Licenses Novel Antifibrinolytic Agents 2Omeros Licenses Novel Antifibrinolytic Agents 3Omeros Licenses Novel Antifibrinolytic Agents 4CutisPharma Launches New Prescription Mouthwash Kits Expanding Product Line 2
(Date:4/17/2014)... pain relief targets that could be used to ... King,s College London made the discovery when researching ... of the body. , Dr Marzia Malcangio said: ... pain generation and our findings could help chemotherapy ... One potential side effect of some chemotherapy drugs ...
(Date:4/17/2014)... Colo. (April 17, 2014) Two recent papers ... researcher and colleagues may help scientists develop treatments ... Yellow fever, Japanese encephalitis and other disease-causing flaviviruses. ... biochemistry and molecular genetics at the School of ... Howard Hughes Medical Institute, and colleagues recently published ...
(Date:4/17/2014)... MAYWOOD, Il. (April 17, 2014) Doctors who ... disease called lymphangioleiomyomatosis (LAM) can face an agonizing ... progression of the disease and help relieve shortness ... lung transplants, and sirolimus can cause potentially fatal ... said pulmonologist Dr. Daniel Dilling, medical director of ...
(Date:4/17/2014)... Boston University School of Medicine (BUSM) have discovered ... in an experimental model. The findings, reported in ... Abuse , may lead to more effective treatments ... one of the leading causes of illness and ... economic impact by limiting the productivity of workers ...
(Date:4/17/2014)... NEW YORK (17 April 2014) Population Council scientists and ... is safe, stable, and can prevent the transmission of ... and rectum in animals: HIV, herpes simplex virus 2 ... provides the first data that the gel is effective ... of efficacy in the vagina against all three viruses ...
Breaking Medicine News(10 mins):Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2
... Dr Mukesh Haikerwal, today congratulated the Government on a ... // with the AMA, and which delivers for patients. ... that the draconian conditions and red tape associated with ... ,'The Government has agreed that the expertise in prescribing ...
... especially the mentally-ill patients and their caregivers. The speech revived ... which would permit the use of obligatory powers to enable ... present ‘treatability test’. ,The infamous ‘Bournewood gap’ is ... of the new bill, which will seek to improve the ...
... banned the use of hookah, or hubble-bubble, in the Pakistani ... were spoiling the younger// generation. ,A way of ... South Asia and the Middle East, the hookah, known as ... and motels in Pakistan, The Daily Times said. ...
... more delays in getting the lab results! - Says ... from University of Georgia has developed a diagnostic test using ... influenza, HIV, RSV etc., in just 60 seconds or even ... technique – which is detailed in the November issue of ...
... that about one in 10 U.S. adults suffer chronic pain that ... Americans have increased to a record average of just short of ... from the Centers for Disease Control and Prevention. ,The ... 80 years and nearly 75 for males. The gap in life ...
... know that they shouldn't smoke or be around smokers ... at a young age. In addition, a new research ... could develop serious liver injuries due to the effects ... research performed at Washington University School of Medicine in ...
Cached Medicine News:Health News:Government Strikes Right Balance with PBS Reform 2Health News:Nanotechnology Used For Detecting Viruses 2Health News:Nanotechnology Used For Detecting Viruses 3Health News:Non-Steroidal Anti-Inflammatory Drugs Can Cause Liver Damages 2Health News:Non-Steroidal Anti-Inflammatory Drugs Can Cause Liver Damages 3
... PLUS pachometers are acknowledged to be the ... pachometers available. These benefits are due to ... and smallest tip footprint available coupled with ... for every displayed reading. Thus corneal thickness ...
... versatile and uncomplicated use of the Leica ... obtained make it the instrument of choice ... cryostat applications. The open top stainless steel ... accessible and offers ample space for convenient ...
... the new style of Bright cryostat. ... OTF/AS cryostat, the new OTF5000 incorporates ... ever-reliable and powerful 5040 microtome. A ... package deals makes the range of ...
... The Leica TP1020 product family are ... a perfect combination of approved technology with ... processing and maximum safety for tissues at ... engineering design based on proven precision mechanics ...
Medicine Products: